BGNE (BeOne Medicines) Gross Profit Margin

Corporate emblem and logo of BeOne Medicines (BGNE)

Geopolitical risks and R&D costs are creating financial pressure, yet the expansion strategy and the displacement of legacy drugs in the US and Europe offset these threats for BeiGene, Ltd. (BGNE). The gross income metric in the GURU.Markets system confirms the effectiveness of this model, where the current figure stands at 87.40. Modern plants in China and a biopharmaceutical complex in New Jersey guarantee the stability of the business.

BGNE - BeOne Medicines Gross Margin over the range 07/04/2022 - 11/20/2026

Analytical breakdowns and data insights for company BeiGene, Ltd. (BGNE)

- market price and analyst price targets:
- business market valuation indicators:
Summary company analysis:BeiGene - BGNE
Manufactured products of BeiGene Ltd

Fundamental asset selection requires analyzing cost management efficiency through key reporting metrics. Gross margin measures the portion of revenue remaining after paying direct production costs, reflecting the business's internal resilience to raw material inflation. For BeiGene, Ltd. (BGNE), this metric is critical, as colossal expenditures on global oncology research and geopolitical pressure on R&D chains directly determine the trend on the gross margin chart.

Direct competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|UroGen Pharma - Return on Gross Profit|Gross Profit Rate BCAX|PSNL - Gross Profitability|Return on Sales by Gross Profit Erasca Oncology ERAS|delcath.com (DCTH) - Gross Profitability|Y-mAbs Therapeutics - Gross Profit Rate|AURA (Aura Biosciences Inc) - Gross Margin|Gross Profit Margin candeltx.com CADL|Gross Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Gross Profit Rate|Gross Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Gross Profitability|TuHURA Biosciences Inc. - Gross Margin|TARA - Gross Margin|FATE (Fate Therapeutics) - Return on Gross Profit|Return on Gross Profit Aadi Bioscience, Inc.|Return on Gross Profit TCRX|Gross Profitability CSBR|Gross Margin XBIT|Return on Sales by Gross Profit CEL-SCI Corp.|Gross Profitability ostherapies.com OSTX|RADX: Gross Return on Sales|ARTV: Return on Gross Profit|ANL (Adlai Nortye) - Gross Return on Sales|Veru (VERU) - Gross Profitability|Return on Gross Profit Tempest Therapeutics Inc|Gross Profitability Xilio Therapeutics|Gross Return on Sales RENB (Renovaro Inc.)|Gross Profitability Mural Oncology PLC (MURA)|Gross Margin Kairos Pharma (KAPA)|Gross Profitability onkuretherapeutics.com OKUR|GDTC: Gross Return on Sales|CRIS: Return on Gross Profit|apollomicsinc.com (APLM) - Return on Gross Profit|THAR: Gross Margin|Return on Gross Profit Advanced Biomed Inc.|Return on Gross Profit GNPX|Gross Return on Sales CLDI (Calidi Biotherapeutics)|Gross Margin SBFM|Xenetic Biosciences, Inc. - Gross Return on Sales|Gross Profitability Salarius Pharmaceuticals SLRX|Gross Margin purple-biotech.com PPBT|AONC - Gross Profitability|Checkpoint Therapeutics, Inc. (CKPT) - Return on Gross Profit|ELEV (Elevation Oncology, Inc.) - Return on Gross Profit|iCAD Inc. - Gross Profit Rate|Return on Gross Profit IKNA|Gross Margin notablelabs.com|Return on Gross Profit VIRX (Viracta Therapeutics Inc.)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit